AGTR1 and Parkinson disease: Indeed, blocking AT1 receptors with specific antagonists, such as candesartan or telmisartan, reduced dopaminergic degeneration [119,120,121,122,123,124] and increased neurogenesis [125,126] in animal models of PD.